BIIB-057
CAS: 1370261-96-3
Ref. 3D-VEC26196
| 1mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Información del producto
- 2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide
BIIB-057 is a monoclonal antibody that binds to the 2-adrenergic receptor and blocks the signal transduction of the inflammatory response. BIIB-057 has been shown to inhibit the activation of primary cells from patients with bowel disease, and to have a clinical relevance in treating inflammatory bowel disease. BIIB-057 inhibits the pro-apoptotic protein, AIF, which is responsible for apoptosis in cancer cells. This drug also blocks cell signaling pathways, such as Toll-like receptor 4 (TLR4) and TLR9, found on endothelial cells and macrophages. BIIB-057 is an immunoglobulin G1 kappa humanized monoclonal antibody that targets PD-L1 and PD-L2.
Propiedades químicas
Consulta técnica sobre: 3D-VEC26196 BIIB-057
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
